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Abstract
Background: In unilateral neuropathic pain. e.g. after peripheral nerve injury, both positive and negative sensory
signs occur often, accompanied by minor but equally directed contralateral sensory changes. To mimic this feature,
we experimentally aimed to induce concomitant c-fibre sensitization and block in healthy subjects and analyzed
the bilateral sensory changes by quantitative sensory testing (QST) using the protocol of the German Research
Network on Neuropathic Pain.
Methods: Twenty eight healthy subjects were firstly randomized in 2 groups to receive either topical capsaicin
(0.6%, 12 cm2, application duration: 15 min.) or a lidocaine/prilocaine patch (25/25 mg, 10 cm2, application duration:
60 min.) on the right volar forearm. Secondly, 7–14 days later in the same area either at first capsaicin (for 15 min.) and
immediately afterwards local anesthetics (for 60 min.) was applied (Cap/LA), or in inversed order with the same
application duration (LA/Cap). Before, after each application and 7–14 days later a QST was performed bilaterally.
Statistics: Wilcoxon-test, ANOVA, p < 0.05.
Results: Single application of 0,6% capsaicin induced thermal hypoesthesia, cold hypoalgesia, heat hyperalgesia
and tactile allodynia. Lidocaine/prilocaine alone induced thermal and tactile hypoesthesia as well as mechanical
and cold hypoalgesia, and a heat hyperalgesia (to a smaller extent). Ipsilaterally both co-applications induced a
combination of the above mentioned changes. Significant contralateral sensory changes occurred only after the
co-application with concomitant sensitization and hypoesthesia and comprised increased cold (Cap/LA, LA/Cap)
and mechanical detection as well as cold pain threshold (LA/Cap).
Conclusion: The present experimental model using combined application of capsaicin and LA imitates partly the
complex sensory changes observed in patients with unilateral neuropathic pain and might be used as an additional
surrogate model. Only the concomitant use both agents in the same area induces both positive and negative sensory
signs ipsilaterally as well as parallel contralateral sensory changes (to a lesser extent).
Trial registration: ClinicalTrials.gov Identifier NCT01540877, registered on 23 February 2012.
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Background
Treating neuropathic pain is challenging, especially in
the face of the low response rate [1]. One reason for the
limited treatment response in neuropathic pain could be
that there are different underlying pathomechanisms
across all entities [2–6]. One subgroup presents pre-
served sensory function in combination with thermal
hyperalgesia, the other is characterized by predominant
sensory loss for thermal and mechanical stimuli. In a
third group signs for sensory loss and gain coexist pro-
ducing combination of hyperalgesia and numbness in
the same painful, e. g. in about 70% in postherpetic
neuralgia (PHN) or 60% in peripheral nerve injury [7, 8].
Therefore, for translational research appropriate
human experimental pain models are needed, mimicking
most of the characteristic clinical signs and their above
mentioned relevant combination. Yet, most of the
human pain models concentrate either on sensory gain
(hyperalgesia induced by electrical stimulation, intrader-
mal capsaicin, topical capsaicin or topical menthol) or
sensory loss, induced by ischemia or nerve compression
[9, 10]. However, none of these surrogate models has
documented the concomitant occurrence of sensory loss
and gain, although they have been observed both in ani-
mal models after unilateral nerve damage and in unilateral
pain syndromes (e.g. complex regional pain syndrome
(CRPS), trigeminal neuralgia and PHN [11–13]). This
contralateral reaction parallel the ipsilateral sensory
changes usually in the same direction (i.e. loss and gain,
respectively) [14, 15]. Unfortunately, the contralateral
change in the human surrogate pain models have not been
studied extensively yet. Several potential mechanisms for
the mirror-image contralateral changes in patients and in
the animal models have been discussed, and the hypoth-
esis, that the these changes are mediated by central
nervous mechanisms, e.g. activation of contralateral hom-
onymous neurons or spinal interneurons has been pro-
claimed as more likely rather than systemic circulating
factors, released by the lesioned nerve [14].
The need for experimental designs that mimic clinical
signs, including contralateral effects, has been acknowl-
edged as a prerequisite for further research [16]. Also, it
has been reported that intracutaneous capsaicin injec-
tion in healthy subjects elicited secondary hyperalgesia
coexisting with secondary tactile hypoesthesia [17], indi-
cating that the surrogate pain model based on a short
lasting intervention is able to induce central nervous
plasticity changes in an area outside the topical applica-
tion, at least ipsilaterally. Therefore, at a first step, we
intended to mimic the above mentioned combined gain
and loss symptomatology, found in patients with neuro-
pathic pain, in one limited area in healthy subjects. We
have examined the sensory alterations after combined C-
fiber block and C-fiber sensitization by local anesthetics
(LA) and capsaicin 0.6%, respectively, in both different
application orders (sensitization of blocked C-fibers and
block of sensitized C-fibers) compared to the sensory
changes induced by each of both substances alone. Aim
of the study was to prove if the concomitant application
of capsaicin and LA, inducing C-fiber block and C-fiber
sensitization, is superior to the single application of both
agents in generating an ipsilateral combination of posi-
tive and negative signs, and contralateral sensory
changes mirroring the symptoms observed in a subgroup
of patients with neuropathic pain.
Methods
Study design
The study consists of two experimental blocks each of
them including 2 study arms, performed all together on
three sessions with 7–14 days between them (Fig. 1). At
first, subjects were randomized to receive either applica-
tion of topical capsaicin 0.6% or local anesthetics (LA)
alone. Quantitative sensory testing (QST) according to
the DFNS protocol was performed immediately before and
after the LA-application, and 7–14 days later. In the case
of capsaicin application, QST was performed additionally
immediately before the application, immediately after the
application during ongoing capsaicin-induced pain (only
thermal and tactile detection, and mechanical pain
threshold), as well as after the spontaneous resolution
of the capsaicin induced ongoing pain during C-fiber
sensitization and 7–14 days later. In the second block
after randomization, the subjects received a combined
application of either first capsaicin 0.6% and afterwards
LA, or both agents in the opposite sequence. QST was
performed immediately before the intervention, imme-
diately after that and 7–14 days later. The experiments
are described in detail below.
A sample size calculation was performed using unpub-
lished data from a study on the sensory changes after
topical application of capsaicin 0.6% using QST according
to the DFNS (Binder et al. oral personal communication,
Jan/2011) and revealed for a power of 80%, type I error of
0.5 and an estimated drop-out rate of 5% a sample size of
at least 14 subjects per study arm.
Subjects
After approval by the local ethics committee of the Faculty
of Medicine, Ruhr-University Bochum (Ref-Nr: 3643-11,
23.02.2011; trial registration number: ClinicalTrials.gov
Identifier NCT01540877, registered on 23 February 2012)
and written informed consent 30 right-handed healthy
volunteers > 18 years old were recruited using a check list
established by the IMI-Europain project after medical his-
tory appraisal and short clinical examination [18]. Subjects
were recruited among students, relatives and hospital staff
by SP, who was student herself at the time of recruitment,
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to avoid coercion. Most of the subjects were recruited by
advertisement or by word-of-mouth recommendation by
subjects who have already participated in the study. It was
explicitly offered to abort the study participation in case of
unbearable pain.
Exclusion criteria were defined according to the re-
cently published recommendations by Gierthmühlen et
al. [18], i.e. insufficient German language skills, history
of any severe internal, neurological or dermatological
diseases, substance abuse, manifest psychiatric diseases,
chronic and acute pain, any medication intake (except
contraceptives in females) regularly or on demand dur-
ing the last 14 days before study inclusion and during
the study period, pregnancy, nursing, abnormal sensory
profile in the quantitative sensory testing (QST) with
side-to-side differences beyond the normal range [19] at
baseline and participation in clinical trials during the last
month. Study-specific exclusion criteria were hypersensi-
tivity to lidocaine or other amide-type anesthetics and
hereditary or acquired methemoglobinemia.
Two subjects were excluded: one had an abnormal
side-to-side differences during the baseline QST, the
other developed acute pain due to a metacarpal fracture
during the study period. Thus, 28 subjects were enrolled
for statistical analysis.
Experiments
The study design is presented in short in Fig. 1.
Day 1
Participants were randomized into two groups after
baseline QST. In the first study arm of the first study
block (Cap) we unilaterally applied bonded gaze
(12 cm2) containing 0,4 ml capsaicin solution (0.6% in
45% ethanol, 0.025 M) in the middle of the right volar
forearm for 15 min, covered by a transparent plastic
dressing to prevent evaporation [20, 21]. The pain inten-
sity was reported on an 11-point numeric rating scale
(NRS, 0-10) every 5 min during the application. During
acute ongoing pain we assessed the cold, warm and
mechanical detection thresholds and the mechanical
pain thresholds at the application site and contralateral.
After spontaneous resolution of the ongoing capsaicin-
induced pain a complete QST was performed in the
same areas. The time, when the skin hypersensitivity in
the area of capsaicin application recovered, was reported
on day 2.
In the second study arm of the first study block a
plaster with LA containing 25 mg prilocaine and 25 mg
lidocaine (EMLA®, AstraZeneca, 10 cm2) was applied in
the middle of the right volar forearm for 60 min. After-
wards, a complete QST was performed in the application
site and contralateral.
Day 2
Seven to fourteen days later after a second randomization
and another baseline QST, in the first study arm of the
second study block capsaicin was applied for 15 min and
then the lidocaine/prilocaine plaster was applied for
60 min (as described above, Cap/LA-group). Ongoing pain
intensity was recorded every 5 min during the capsaicin
application and every 15 min during the LA application.
In the second study arm of the second study block the
lidocaine/prilocaine patch was applied for 60 min and
afterwards a capsaicin bonded gaze was applied for another
15 min (as described above, LA/Cap-group). The pain
intensity was recorded only during capsaicin applica-
tion every 5 min.
Fig. 1 Study design. QST: quantitative sensory testing; CDT, cold detection threshold; MDT, mechanical detection threshold; MPT, mechanical pain
threshold; WDT, warm detection threshold
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Immediately after removal of both substances the
areas of allodynia and hyperalgesia were mapped (see
below) and QST was again performed. The time, when
the skin hypersensitivity in the area of capsaicin applica-
tion recovered, was reported on day 3.
Day 3
Another 7–14 days later QST was assessed bilaterally in
the previously examined areas.
Sensory assessment
Quantitative sensory testing (QST)
QST was performed according to the standardized
protocol of the German Research Network on Neuro-
pathic Pain (DFNS) [19], assessing a complete sensory
profile after measuring the skin temperature using an in-
frared thermometer. The following parameters were
assessed exactly following the DFNS protocol: cold and
warm detection thresholds (CDT, WDT), cold and heat
pain thresholds (CPT, HPT), the ability to discriminate
between consecutive warm and cold stimuli (thermal
sensory limen, TSL), including any paradoxical heat
sensation (PHS, i.e. perceiving cold stimuli as warm),
mechanical detection thresholds (MDT), mechanical
pain thresholds (MPT), mechanical pain sensitivity
(MPS) and temporal summation to repeated pain stimuli
(wind-up ratio, WUR), vibration detection thresholds
(VDT), pressure pain threshold (PPT) and dynamic
mechanical allodynia (DMA). QST was performed at the
department’s certified QST lab by a trained investigator
(S.P.), according to the published standards for quality
assessment [22].
Mapping
After removal of all substances, the areas of tactile
hypoesthesia and allodynia (using a Q-tip) and pinprick
hyperalgesia (using a microfilament, Twin Tip®, 10 g ~
9,8mN) were assessed, as previously described [23]. The
perception areas of tactile hypoesthesia, allodynia and
pinprick hyperalgesia were marked on the skin, copied
to a transparent sheet and calculated (cm2) using Auto-
CAD (Version 2012).
Questionnaires
The Hospital Anxiety and Depression Scale (HADS) was
assessed in the validated German version, including the
degree of depression and anxiousness (abnormal: score >
7) [24, 25]. The Pain Catastrophizing Scale (PCS) was
used to determine the relation of negative expectations,
emotional distress and pain maintenance (catastrophi-
zers: score > 24, non-catastrophizers: score < 15) [26, 27].
The individual sensitivity to painful events in everyday
life situations on the NRS (0-10) was measured by the
Pain Sensitivity Questionnaire (PSQ) [28].
Statistics
QST parameters were transformed into z-values [19]
referring to our baseline testing on the volar forearm in
all 28 subjects:
z‐value ¼ meansingle subject–meanbaseline healthy subjects
 
=SDbaselinehealthy subjects
A z-score of zero represents the baseline mean. Z-
scores > 0 show a higher sensitivity (hyperesthesia, hyper-
algesia) compared to the baseline mean, z-values < 0 show
a lower sensitivity (hypoesthesia, hypoalgesia). Z-values of
0 ± 1.96 represent the 95% confidence interval of the base-
line data.
The data before and after the intervention were com-
pared using Wilcoxon-test. The hyperalgesia and allody-
nia area sizes and the pain intensities during capsaicin
application were compared between the three groups
Cap, Cap/LA and LA/Cap, and also between the sub-
groups of study members showing contralateral sensory
alterations and those without any contralateral sensory




After application of only capsaicin all subjects developed
ipsilaterally flare and burning ongoing pain, 7 additionally
edema and one reported itch.
After single application of LA we observed central
paleness in the plaster covered skin due to vasoconstric-
tion in 12 of the 14 subjects. Two of them presented
flare in the plaster adhesion surface.
In the Cap/LA-group all participants developed flare
after the capsaicin application, 6 additionally edema and
one reported itch. After the LA-application we observed
in 5 only flare, in 6 - flare with central paleness and in
further 3 - only central paleness.
In the LA/Cap-group after the LA-application 4 sub-
jects had no dermal alterations, 2 developed flare and 8
- central paleness. After the capsaicin application all 14
participants developed flare, 6 demonstrated swelling
and one reported itch.
Questionnaires
The PSQ revealed low values, without differences between
the study groups (Table 1). The HADS depression score
detected normal values. The anxiety score was marginally
increased in one subject (8 points) without clinical symp-
toms. The PCS identified 24 as non-catastrophizer, one
was classified as catastrophizer.
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Intensity of the ongoing pain in the area of capsaicin
application
Ongoing pain was reported only ipsilaterally to the
capsaicin application. The mean pain intensity in the
Cap-group and in both groups with combined applica-
tion (LA/Cap-group and Cap/LA-group) was similar
immediately after topical capsaicin (Table 1, Fig. 2).
However, in the LA/Cap-group acute pain terminated
in only 5 participants within 48 ± 14 min after the
patch removal, while the other 9 subjects perceived
ongoing pain until the end of the study procedures. In
contrast, in the Cap/LA-group the ongoing pain
Table 1 Clinical data
Part 1. Single substance
application
Part 2. Combined substance
applicationa
Cap-group LA-group Cap/LA-group LA/Cap-group
(n = 14) (n = 14) (n = 14) (n = 14)
gender (female, n (%)) 9 (64%) 8 (57%) 9 (64%) 8 (57%)
age (years, mean ± SD) 30 ± 14 30 ± 13 31 ± 13 30 ± 14
BMI (kg/m2) 23 ± 2 24 ± 4 23 ± 3 24 ± 3
HADS A-Score 3.9 ± 2.3 2.9 ± 2.0 2.9 ± 2.1 3.8 ± 2.3
HADS D-Score 1.5 ± 1.6 0.6 ± 0.9 0.9 ± 1.2 1.3 ± 1.5
Pain sensitivity score (PSQ), total 2.7 ± 0.9 2.5 ± 0.9 2.5 ± 0.8 2.7 ± 1
Pain catastrophizing scale (PCS), total 7.1 ± 8.2 10.1 ± 7.4 8.5 ± 7.7 8.6 ± 8.2
Duration of acute capsaicin-induced pain (min) 32 ± 7*** not applicable 83 ± 30.8*** 48 ± 14***c
Mean spontaneous pain intensity after capsaicin gauze removal (NRS 0-10) 6.7 ± 1.3 not applicable 6.7 ± 1.8 6.4 ± 1.9
Duration of reported hypersensitivity after capsaicin application (days) 1 ± 0.5 not applicable 0.8 ± 0.5 0.9 ± 0.5
Area of allodynia (cm2) 60 ± 39* not applicable 32 ± 22* 48 ± 17*
Area of pinprick hyperalgesia (cm2) 66 ± 43 not applicable 57 ± 30 54 ± 25
Area of tactile hypoesthesia (cm2) not applicable 9 ± 4 not applicable not applicable
Skin temperature change after removal of the applied substances (Δ °C)b 1.4 ± 1.4 -1.1 ± 1.1** 0.7 ± 1.5 1.8 ± 1.7
Cap single capsaicin application, LA single local anesthetics application, Cap/LA combined application of 1. capsaicin and 2. local anesthetic, LA/Cap combined
application of 1. local anesthetic and 2. Capsaicin, HADS hospital anxiety and depression score, HADS-A-Score anxiety score, HADS-D-Score depression score, SD
standard deviation
aParticipants of the first part of the experiment are also involved in the second part. Therefore, values on the demographic characteristics, HADS, PSQ and PCS are
redistributed for the data presentation of the part 2 of the study
bPositive values indicate higher skin temperature after the substance application, negative values - lower temperature, respectively
cThe mean value for the duration of acute capsaicin-induced pain was calculated only based on 5 subjects, the rest 9 subjects were still sensing ongoing pain at
the end of the study procedures
*Significant difference (p < 0.05) between all three groups (ANOVA)
***Significant difference (p < 0.001) between all three groups (ANOVA)
Fig. 2 Intensity of ongoing pain during capsaicin application in the group with application of a single agent (Cap, black) as well as in the groups
with combined application of first capsaicin and then local anesthetics (Cap/LA, gray) and of first local anesthetics and then capsaicin (LA/Cap, white)
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terminated in all 14 subjects within 83 ± 30.8 min
(Chi2-Test, p < 0.01).
Ipsilateral area of hyperalgesia, allodynia and
hypoesthesia
The pinprick hyperalgesia area was mainly identical to
the area of flare, nonetheless, differing from the dynamic
allodynia area with high inter-individual variance, but
without significant differences between all three groups.
The size of the area with allodynia were significantly
larger in the LA/Cap-group compared to the Cap/LA-
group, but both were significantly smaller than after cap-
saicin application alone (Table 1). An area of tactile
hypoesthesia was found only in the LA-group, mostly
identical with the lidocaine/prilocaine plaster size.
Sensory changes in QST parameter
All data are summarized in Additional file 1: Table S1
and Additional file 2: Table S2.
Ipsilateral sensory changes
After application of only capsaicin the sensory profile
showed both significant negative signs (for CDT during
both acute pain and capsaicin-induced evoked pain after
spontaneous pain relief, for WDT and for CPT) as well
as positive signs for HPT, MPS and WUR (Fig. 3a).
Three subjects reported PHS and 8 showed DMA. After
single LA-application the sensory profile was dominated
by significant sensory loss for several detection and pain
thresholds: CDT, MDT, WDT (to a lesser extent) MPT,
PPT, MPS and WUR, with the exception of HPT, which
significantly decreased (Fig. 3b). After combined applica-
tion of both agents (Cap/LA-group and LA/Cap-group)
the thermal detection and pain thresholds were similar to
the ones after capsaicin application alone, with additional
signs for significant sensory loss for MDT, MPT and MPS
(only in the Cap/LA-group) and sensory gain for PPT
(only in the LA/Cap-group) (Fig. 3c, d). In both groups of
combined application (Cap/LA-group and LA/Cap-group)
all subjects developed DMA.
Contralateral sensory changes
After application of only capsaicin a significant slight
increase of only CDT was observed contralateral to the
capsaicin application site only during the time of acute
ongoing pain (in 10 of 14 subjects), but not during
hypersensitivity after the spontaneous recovery of the
capsaicin-induced pain (Fig. 4). After single LA-
Fig. 3 Ipsilateral z-profiles measured before (black circuits) and after single application of (a) capsaicin or (b) local anesthetics, as well as after combined
application of (c) first capsaicin then local anesthetics and (d) first local anesthetics then capsaicin (white circuits) as well as back to baseline 7-14 days
later (black diamonds) on the subjects’ right forearm. Z-values between -1.96 and +1.96 represent the 95% confidential interval of the baseline
measurement in the whole group of 28 healthy subjects, z-values greater than 0 demonstrate a sensory gain compared to the group mean of
the baseline QST, while z-values less than 0 demonstrate a sensory loss. CDT, cold detection threshold; CPT, cold pain threshold; DMA, dynamic mechanical
allodynia; HPT, heat pain threshold; MDT, mechanical detection threshold; MPS, mechanical pain sensitivity; MPT, mechanical pain threshold;
NRS, numeric rating scale; PHS, paradoxical heat sensation; PPT, pressure pain threshold; TSL, thermal sensory limen; VDT, vibration detection
threshold; WDT, warm detection threshold; WUR, wind-up ratio
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application the contralateral detection thresholds
remained unchanged. After combined application of first
capsaicin then LA (Cap/LA-group) CDT again was sig-
nificantly higher contralaterally (in 11 of 14 participants,
Additional file 3: Figure S1A). After combined applica-
tion of first LA then capsaicin (LA/Cap-group) CDT (in
10 of 14 subjects), MDT (in 11 of 14 subjects) and CPT
(in 11 of 14 subjects) were significantly higher contralater-
ally (Additional file 3: Figure S1B). Ipsilateral pain inten-
sity did not correlate with the amount of the contralateral
sensory changes of CDT and MDT.
Discussion
We applied consecutively topical capsaicin and local an-
aesthetics to induce concomitant sensory gain (e.g.
sensitization) and loss (i.e. hypoesthesia). In summary, the
ipsilateral application of only capsaicin or only LA induced
the expected ipsilateral sensory changes. Capsaicin appli-
cation had only a short-lasting effect on the CDT on the
contralateral side, which increased only during the short
period, in which capsaicin led to ongoing pain. In contrast,
the application of LA had no effect on the contralateral
sensory function. Interestingly, after combined application
of capsaicin and LA, independently of the sequence, CDT
increased contralaterally for a longer period than the
period with the ongoing pain. Additionally, in the LA/
Cap-group the MDT increased and CPT decreased con-
tralaterally to the application site. All contralateral changes
followed the same direction as the changes observed in
the corresponding thresholds on the application site but to
a lesser extent. Positive ipsilateral signs were not mirrored.
The challenge of translational pain research
Hitherto reported human experimental pain models
have focused on mechanisms inducing sensory gain or
loss ipsilateral. Examples of a surrogate model are the
topical or intradermal capsaicin application, evoking plus
signs like pinprick hyperalgesia and allodynia [7] and
topical menthol in high concentration inducing cold
hyperalgesia, but both mostly no hypoesthesia (except
for cold hypoesthesia after capsaicin application) [29, 30].
On the other hand, the transient ischemic nerve fiber
block induced only sensory loss [31–33]. To our know-
ledge, there was no such a human pain model focusing on
the induction of concomitant sensory loss and gain signs,
which were described on the capsaicin model and the
electrical stimulation [17, 34].
Fig. 4 Contralateral z-profiles measured before (black circuits) and after single application of (a) capsaicin or (b) local anesthetics, as well as after
combined application of (c) first capsaicin then local anesthetics and (d) first local anesthetics then capsaicin (white circuits) as well as back to
baseline 7-14 days later (black diamonds) on the subjects’ right forearm. Z-values between -1.96 and +1.96 represent the 95% confidential interval
of the baseline measurement in the whole group of 28 healthy subjects, z-values greater than 0 demonstrate a sensory gain compared to the
group mean of the baseline QST, while z-values less than 0 demonstrate a sensory loss. Red borders indicate significant contralateral changes.
CDT, cold detection threshold; CPT, cold pain threshold; DMA, dynamic mechanical allodynia; HPT, heat pain threshold; MDT, mechanical detection
threshold; MPS, mechanical pain sensitivity; MPT, mechanical pain threshold; NRS, numeric rating scale; PHS, paradoxical heat sensation; PPT, pressure
pain threshold; TSL, thermal sensory limen; VDT, vibration detection threshold; WDT, warm detection threshold; WUR, wind-up ratio
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Indeed, the phenomenon of concomitant sensory loss
and gain is frequent in patients with chronic neuropathic
pain and has recently been described in about 50% of
different neuropathic pain in different entities [7, 8], par-
ticularly in PHN [35] and after peripheral nerve injury,
but also in CRPS [11, 36, 37] and central post-stroke
pain [38]. Thus, our experimental pain model with tran-
sient sensory loss and gain mimics a part of the sensory
dysfunction of neuropathic pain states. The topical sub-
stance application makes it easy to handle. Though, this
pain model, as all others previously described, can imitate
only some aspects of the clinical states but not to the
complex symptomatology of chronic pain [10], because it
is obvious that for ethical reasons a lesion or disease of
the somatosensory system in healthy volunteers cannot be
induced. This may generally limit the use of human
surrogate models for neuropathic pain and represents
one critical point for any translational pain research.
For instance, they are usually based on short acting
interventions, which are hard to compare with features
of neuropathic pain that has developed chronically due
to lesion of the somatosensory system, leading to well
established mechanisms such as central and peripheral
sensitization, enhanced peripheral fiber excitability,
abnormal alteration in cord circuitry, etc.
Ipsilateral sensory changes
We used topical capsaicin as an established model to
induce positive sensory signs in healthy subjects. The
ipsilateral heat hyperalgesia, enhanced MPS and DMA
after application of only capsaicin develop due to per-
ipheral sensitization after TRPV1-receptor activation in
epidermal C-fibers [38–40]. The secondary hyperalgesia
and allodynia around the application site suggest cen-
tral sensitization, even after the short lasting applica-
tion [32]. The previously described tactile hypoesthesia
in the secondary area after capsaicin application indicates
additionally selective spinal inhibition of mechanorecep-
tive nerve fibres following the selective excitation of
capsaicin-sensitive C-fibre nociceptors [17]. Interestingly,
capsaicin induced not only positive, but also negative
thermal signs. Remarkably, the largest change from
baseline after capsaicin application was the increase of
the cold detection threshold, although capsaicin has
primary effect on TRPV1, and as such is expected to
affect warm and heat perception most significantly.
Our results of cold hypoesthesia are in line with a pre-
vious study [41]; however, the underlying mechanisms
are unclear. Several peripheral mechanisms for the
inhibition of cold sensation by capsaicin have been
hypothesized [41]. A coexpression of TRPV1 and
TRPM8 receptors has been suggested, where the activa-
tion of one of the receptors probably leads to opposed
functional changes of the other [41–43]. On the other
hand, the capsaicin-induced inflammation leads to release
of bradykinin and prostaglandin E and subsequent shift of
the threshold temperature of TRPM8 expressing neurons
to colder values mediated by protein kinase A [41, 44].
On the other hand, in order to induce negative sensory
signs we applied LA. The ipsilateral thermal and tactile
hypoesthesia and pinprick hypoalgesia after LA-application
alone result from blocking sodium channels on C-fibres
[45, 46]. Yet, we observed a HPT decrease also after lido-
caine/prilocaine application. This finding is in contrast to
our published data on sensory changes after pure lidocaine
(5%) application [46], but in line with a previous study, in
which lidocaine sensitized normal skin for heat [47]. The
heat hyperalgesia seems to underlie a lidocaine-induced
activation and sensitization of TRPV1 and TRPA1 [48].
Applying both substances, we could block sensitized
c-fibers and vice versa sensitize blocked c-fibers in
healthy subjects, depending on the application se-
quence. The ongoing pain intensity after capsaicin 0.6%
was not influenced by the LA-application immediately
before capsaicin, as previously described [49]. However,
the LA-application after capsaicin accelerated the re-
covery of capsaicin-induced ongoing pain. In the Cap/
LA-group the capsaicin-induced mechanical hyperalgesia
was reversible after LA-application, inducing mechanical
hypoesthesia and hypoalgesia. Interestingly, in the LA/
Cap-group the LA-induced mechanical hypoesthesia and
hypoalgesia rose to normal values after capsaicin applica-
tion and the mean allodynia area was significantly larger
than in the Cap/LA-group. We have previously demon-
strated that LA in form of a lidocaine (5%) patch induced
only a partial small fiber block of unpredictable extent
[46]. The different kinetics of the LA-induced sensory
changes in the present study after co-application of LA
and capsaicin suggests that the sensitization after TRPV1-
activation was able to overact the LA-induced block.
Contralateral sensory changes
A slightly increased CDT, MDT and CPT were observed
also in the contralateral mirror skin area (to a lesser ex-
tent compared to ipsilateral) which might suggest central
involvement in the stimulus processing. The contralateral
sensory changes observed in our model indicate again
similarity to the clinical observations, likewise in CRPS
[11], unilateral osteoarthritis pain [50] and unilateral PHN
[12]. Experimental animal studies have already described
congruent contralateral reactions after unilateral nerve
lesion [14]. Contralateral sensory changes have been also
reported in humans, however assessing only single
modalities. Bilateral pinprick hyperalgesia and tactile
allodynia following unilateral capsaicin injection was
measured in healthy subjects and patients with rheuma-
toid arthritis [51]. Cold hypoesthesia and hypoalgesia as
well as tactile hypoesthesia after unilateral topical
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capsaicin application in healthy subjects have also been
described [41, 52].
Exact determination of the underlying mechanisms for
the development of the contralateral sensory changes is
currently impossible. Persistent pain is supposed to sup-
press the primary somatosensory cortical activity that
normally responds to innocuous tactile sensations [52].
The significantly increased CDT after application of only
capsaicin in our study only during ongoing pain sup-
ports this hypothesis. However, we cannot exclude that
psychological aspects play a role in the development of
the contralateral sensory changes, e.g. some effect of dis-
traction during ongoing pain ipsilaterally to the inter-
vention cannot be excluded. On the other hand, the
ongoing pain intensity after capsaicin alone and the ex-
tent of contralateral changes were not related. Further
on, one might argue that the contralateral findings could
be explained by a simple ‘anticipatory’ response, where
the subject tends to respond on the contralateral side
similarly as on the treated side. However, this was the
case only for the detection thresholds in the case of
combined application of local anesthetics and capsaicin
ipsilaterally, whereas the much more pronounced positive
signs after capsaicin application and also the ipsilateral
hypoesthesia after lidocaine application were not mir-
rored. Thus, this hypothesis seems not to be probable.
A further potential mechanism for the contralateral
sensory loss may be a supraspinal descending inhibition
of neuronal dorsal horn activity responses following
nociceptive input [53]. The contralateral hypoesthesia
may also be facilitated due to a contrast phenomenon
compared to the intensely perceived painful stimulus
ipsilateral. Hitherto, this concept was proposed for the
primary visual perception [54], but may also play a role
in nociceptive processing as thalamic filtering mechan-
ism [55, 56]. However, the pain intensity and the extent
of contralateral changes after combined capsaicin and
LA-application were also unrelated, while the hyper-
algesia and allodynia areas were even smaller than after
application of only capsaicin. Cortical alterations may
also be induced by maladaptive stimulus processing af-
fecting central plasticity [23]. Furthermore, commis-
sural interneurons on spinal level may transmit sensory
changes between both body sides [14].
Although the changes we have observed in the present
study were statistically significant in the group analysis,
they were absent in some subjects and are likely to be of
different magnitude compared to the clinical cases of
neuropathic pain. The less pronounced contralateral sen-
sory changes in our model compared to results in patients
with neuropathic pain may be explained by the difference
between changes induced by acute and moderate pain in
healthy subjects (as in our model) and by chronic neuro-
pathic pain. Additionally, the exact temporal maintenance
of the sensory alterations and the exact anatomical spread
of the contralateral changes in our study are unknown
(except for the fact, that they are reversible after 7-14
days). We did not include a study arm with placebo inter-
vention and neither the investigator nor the subjects were
blinded, and this might be a possible limitation based on
the observation bias. However, we refrained from that,
because a blinding could not be possible due to the pro-
nounced spontaneous sensory changes ipsilaterally fol-
lowing the application of local anesthetics and/or
capsaicin, which were obvious for all subjects. An im-
portant inclusion criterion was that all subjects were naïve
for QST and were not informed about the study hy-
potheses, especially the focus on contralateral changes,
thus they were not biased by certain expectations of the
subjects. The above potential mentioned observation
bias is expected to be of only minor extend as all
assessed parameters of the QST are based on the sub-
jects’ response.
Conclusion
In summary, the presented human model with combined
application of capsaicin and LA might be an additional
surrogate model for unilateral neuropathic pain, because
it mimics partly its complex symptomatology. Only the
concomitant use both agents in the same area induces
both positive and negative sensory signs ipsilaterally as
well as parallel contralateral sensory changes. Thus, this
model may be useful to analyse the anti-hyperalgesic
mechanisms of pharmacological and non-medical inter-
vention in the difficult treatment of neuropathic pain.
Additional files
Additional file 1: Table S1. A. QST data after single substance
application (site of application; data are presented as median (range)). B.
QST data after combined substance application (site of application; data
are presented as median (range)). (DOCX 35 kb)
Additional file 2: Table S2. A. QST data after single substance
application (contralateral to the application site; data are presented as
median (range)). B. QST data after combined substance application
(contralateral to the application site; data are presented as median
(range)). (DOCX 34 kb)
Additional file 3: Figure S1. (A) Contralateral changes in the cold
detection threshold of all subjects before and after application of a
combination of capsaicin and local anesthetics as well as 7-14 days later.
(B) Contralateral changes in the mechanical detection threshold of all
subjects before and after application of capsaicin and local anesthetics as
well as 7–14 days later. Gray circuits show the calculated group means.
Red borders indicate significant changes. (TIF 1022 kb)
Abbreviations
CDT: Cold detection threshold; CPT: Cold pain threshold; CRPS: Complex
regional pain syndrome; DFNS: German Research Network on Neuropathic
Pain (Deutscher Forschungsverbund Neuropathischer Schmerz); DMA: Dynamic
mechanical allodynia; HPT: Heat pain threshold; MDT: Mechanical detection
threshold; MPS: Mechanical pain sensitivity; MPT: Mechanical pain threshold;
PHN: Postherpetic neuralgia; PHS: Paradoxical heat sensation; PPT: Pressure
pain threshold; QST: Quantitative sensory testing; TSL: Thermal sensory
Enax-Krumova et al. BMC Neurology  (2017) 17:60 Page 9 of 11
limen; VDT: Vibration detection threshold; WDT: Warm detection threshold;
WUR: Wind-up ratio
Acknowledgements
We are indebted to the subjects who participated in the study for their consent
and co-operation. For demonstration of the pain model using topical and
intradermal capsaicin and the initial discussion we thank Dr. A. Binder (Division
of Neurological Pain Research and Therapy, Department of Neurology,
Christian-Albrechts-Universität Kiel, Germany, Head: Prof. R. Baron) and Dr.
T. Klein (Division of Neurophysiology, Centre of Biomedicine and Medical
Technology, Mannheim, Medical Faculty Mannheim, Ruprecht-Karls-University,
Heidelberg, Mannheim, Germany, Chair: Prof. R.-D. Treede; currently employed
by Mundipharma Research GmbH & Co). We also thank Arch. S. Krumova and
Ing. K. Krumov for helping to calculate the surface of the area of hyperalgesia
and allodynia.
Funding
This study was supported by intramural fundings of the Ruhr University
Bochum (FoRUM: grant number K046-10). The research leading to these
results is also part of the Europain Collaboration, which has received
support from the Innovative Medicines Initiative Joint Undertaking, under
grant agreement no 115007, resources of which are composed of financial
contribution from the European Union’s Seventh Framework Programme
(FP7/2007‐2013) and EFPIA companies’ in kind contribution (see competing
interests).
Regarding the publication fees, we acknowledge support by the Open Access
Publication Funds of the Ruhr-Universität Bochum.
Availability of data and materials
The datasets during and/or analysed during the current study is available from
the corresponding author on reasonable request.
Authors’ contributions
EKK was involved in the conception and design of the study, data analysis
and interpretation, critical revision and approval of the manuscript version to
be published. SP was involved in data acquisition, analysis and interpretation,
wrote the first draft of the paper and approved the final version to be published.
AW was involved in the data interpretation, revised the manuscript critically for
important intellectual content and approved the final version to be published.
CM was involved in the conception and design of the study and in the
data interpretation, revised critically and approved the manuscript version
to be published.
Authors’ information
This work is part of the doctoral thesis of Stephanie Pohl.
Competing interests
None of the authors have any competing interests with regards to this
manuscript.
CM, EK and AW are members of the German Research Network on
Neuropathic pain (BMBF, grants 01EM0107 & 01EM0502). CM and AW are
members of the Europain Collaboration, which has received support from
the Innovative Medicines Initiative Joint Undertaking, under grant agreement
no 115007, resources of which are composed of financial contribution from
the European Union’s Seventh Framework Programme (FP7/2007‐2013) and
EFPIA companies (AstraZeneca, Pfizer, Esteve, UCB-Pharma, Sanofi Aventis,
Grünenthal, Eli Lilly und Boehringer Ingelheim) in kind contribution. CM has
received research grants from Pfizer, MSD, Mundipharma, Grünenthal, Astel-
las, and Lilly; he has also received consultant and/or speaker fees from Astra
Zeneca, Astellas, Pfizer, Mundipharma and Eli Lilly. EK has been a member of
the IMI Europain (see above). She was also supported by intramural fundings
of the Ruhr University Bochum (FoRUM: grant number K046-10, Heinemann
Award 2013) and has received a travel grant from Mundipharma, speaker
fees from Grunenthal and Pfizer. S.P. has no conflict of interests to report.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study protocol was in accordance with the latest version of the Declaration
of Helsinki and approved by the local ethics committee of the Faculty of
Medicine, Ruhr-University Bochum, Germany (Ref-Nr: 3643-11, 23.02.2011).
Before starting the assessment, the study was described in its entirety to
the subjects and they all gave their written informed consent to participate.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Neurology, BG University Hospital Bergmannsheil GmbH,
Ruhr University Bochum, Bürkle-de-la-Camp-Platz 1, D-44789 Bochum,
Germany. 2Department of Pain Medicine, BG University Hospital
Bergmannsheil GmbH Bochum, Ruhr University Bochum, Bochum, Germany.
Received: 21 December 2016 Accepted: 13 March 2017
References
1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH,
Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A,
Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M.
Pharmacotherapy for neuropathic pain in adults: a systematic review and
meta-analysis. Lancet Neurol. 2015;14(2):162–73.
2. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological
mechanisms, and treatment. Lancet Neurol. 2010;9(8):807–19.
3. Baron R, Förster M, Binder A. Subgrouping of patients with neuropathic pain
according to pain-related sensory abnormalities: a first step to a stratified
treatment approach. Lancet Neurol. 2012;11(11):999–1005.
4. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS,
Sindrup SH. The effect of oxcarbazepine in peripheral neuropathic pain depends
on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-
stratified study. Pain. 2014;155(11):2263–73.
5. Mainka T, Malewicz NM, Baron R, Enax-Krumova EK, Treede RD, Maier C.
Presence of hyperalgesia predicts analgesic efficacy of topically applied
capsaicin 8% in patients with peripheral neuropathic pain. Eur J Pain. 2016;
20(1):116–29.
6. Bouhassira D, Attal N. Translational neuropathic pain research: A clinical
perspective. Neuroscience. 2016;338:27–35.
7. Maier C, Baron R, Tolle TR, Binder A, Birbaumer N, Birklein F, Gierthmuhlen J,
Flor H, Geber C, Huge V, Krumova EK, Landwehrmeyer GB, Magerl W,
Maihofner C, Richter H, Rolke R, Scherens A, Schwarz A, Sommer C, Tronnier
V, Uceyler N, Valet M, Wasner G, Treede RD. Quantitative sensory testing in
the German Research Network on Neuropathic Pain (DFNS): somatosensory
abnormalities in 1236 patients with different neuropathic pain syndromes.
Pain. 2010;150(3):439–50.
8. Baron R, Maier C, Attal N, Binder A, Bouhassira D, Cruccu G, Finnerup NB,
Haanpää M, Hansson P, Hüllemann P, Jensen TS, Freynhagen R, Kennedy JD,
Magerl W, Mainka T, Reimer M, Rice AS, Segerdahl M, Serra J, Sindrup S,
Sommer C, Tölle T, Vollert J. Treede RD; German Neuropathic Pain Research
Network (DFNS), and the EUROPAIN and NEUROPAINconsortia… Peripheral
Neuropathic Pain: A mechanism-related organizing principle based on sensory
profiles. Pain. 2017;158(2):261–72.
9. Klein T, Magerl W, Rolke R, Treede RD. Human surrogate models of
neuropathic pain. Pain. 2005;115(3):227–33. Review. Erratum in: Pain. 2006;
120(1-2):224–5.
10. Binder A. Human surrogate models of neuropathic pain: validity and limitations.
Pain. 2016;157 Suppl 1:S48–52.
11. Huge V, Lauchart M, Forderreuther S, Kaufhold W, Valet M, Azad SC, Beyer A,
Magerl W. Interaction of hyperalgesia and sensory loss in complex regional
pain syndrome type I (CRPS I). PLoS One. 2008;3(7), e2742.
12. Oaklander AL, Romans K, Horasek S, Stocks A, Hauer P, Meyer RA. Unilateral
postherpetic neuralgia is associated with bilateral sensory neuron damage.
Ann Neurol. 1998;44(5):789–95.
13. Sinay VJ, Bonamico LH, Dubrovsky A. Subclinical sensory abnormalities in
trigeminal neuralgia. Cephalalgia. 2003;23(7):541–4.
14. Koltzenburg M, Wall PD, McMahon SB. Does the right side know what the
left is doing? Trends Neurosci. 1999;22(3):122–7.
15. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, Treede RD. A new
definition of neuropathic pain. Pain. 2011;152(10):2204–5.
16. Oaklander AL, Brown JM. Unilateral nerve injury produces bilateral loss of
distal innervation. Ann Neurol. 2004;55(5):639–44.
Enax-Krumova et al. BMC Neurology  (2017) 17:60 Page 10 of 11
17. Magerl W, Treede RD. Secondary tactile hypoesthesia: a novel type of pain-
induced somatosensory plasticity in human subjects. Neurosci Lett. 2004;
361(1-3):136–9.
18. Gierthmühlen J, Enax-Krumova EK, Attal N, Bouhassira D, Cruccu G, Finnerup
NB, Haanpää M, Hansson P, Jensen TS, Freynhagen R, Kennedy JD, Mainka T,
Rice A, Segerdahl M, Sindrup SH, Serra J, Tölle T, Treede RD, Baron R, Maier
C. Who is healthy? Pain: Aspects to consider when including healthy volunteers
in QST-based studies- a consensus statement by the EUROPAIN and
NEUROPAIN consortia; 2015 [Epub ahead of print].
19. Rolke R, Baron R, Maier C, Tölle TR, Treede RD, Beyer A, Binder A, Birbaumer
N, Birklein F, Bötefür IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer
GB, Magerl W, Maihöfner C, Rolko C, Schaub C, Scherens A, Sprenger T,
Valet M, Wasserka B. Quantitative sensory testing in the German Research
Network on Neuropathic Pain (DFNS): standardized protocol and reference
values. Pain. 2006;123(3):231–43.
20. Schattschneider J, Zum Buttel I, Binder A, Wasner G, Hedderich J, Baron R.
Mechanisms of adrenosensitivity in capsaicin induced hyperalgesia. Eur J
Pain. 2007;11(7):756–63.
21. Wasner G, Lee BB, Engel S, McLachlan E. Residual spinothalamic tract pathways
predict development of central pain after spinal cord injury. Brain. 2008;
131(Pt 9):2387–400.
22. Vollert J, Mainka T, Baron R, Enax-Krumova EK, Hüllemann P, Maier C, Pfau
DB, Tölle T, Treede RD. Quality assurance for Quantitative Sensory Testing
laboratories: development and validation of an automated evaluation tool
for the analysis of declared healthy samples. Pain. 2015;156(12):2423–30.
23. Geber C, Magerl W, Fondel R, Fechir M, Rolke R, Vogt T, Treede RD, Birklein
F. Numbness in clinical and experimental pain–a cross-sectional study
exploring the mechanisms of reduced tactile function. Pain. 2008;
139(1):73–81.
24. Hinz A, Schwarz R. Anxiety and depression in the general population:
normal values in the Hospital Anxiety and Depression Scale. Psychother
Psychosom Med Psychol. 2001;51(5):193–200.
25. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta
Psychiatr Scand. 1983;67(6):361–70.
26. Meyer K, Sprott H, Mannion AF. Cross-cultural adaptation, reliability, and validity
of the German version of the Pain Catastrophizing Scale. J Psychosom Res.
2008;64(5):469–78.
27. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development
and Validation. Psychol Assess. 1995;7(4):524–32.
28. Ruscheweyh R, Marziniak M, Stumpenhorst F, Reinholz J, Knecht S. Pain
sensitivity can be assessed by self-rating: Development and validation of
the Pain Sensitivity Questionnaire. Pain. 2009;146(1-2):65–74.
29. Binder A, Stengel M, Klebe O, Wasner G, Baron R. Topical high-concentration
(40%) menthol-somatosensory profile of a human surrogate pain model.
J Pain. 2011;12(7):764–73.
30. Wasner G, Schattschneider J, Binder A, Baron R. Topical menthol–a human
model for cold pain by activation and sensitization of C nociceptors. Brain.
2004;127(Pt 5):1159–71.
31. Baumgartner U, Magerl W, Klein T, Hopf HC, Treede RD. Neurogenic hyperalgesia
versus painful hypoalgesia: two distinct mechanisms of neuropathic pain. Pain.
2002;96(1-2):141–51.
32. Magerl W, Fuchs PN, Meyer RA, Treede RD. Roles of capsaicin-insensitive
nociceptors in cutaneous pain and secondary hyperalgesia. Brain. 2001;
124(Pt 9):1754–64.
33. Ziegler EA, Magerl W, Meyer RA, Treede RD. Secondary hyperalgesia to
punctate mechanical stimuli. Central sensitization to A-fibre nociceptor
input. Brain. 1999;122(Pt 12):2245–57.
34. De Col R, Maihöfner C. Centrally mediated sensory decline induced by
differential C-fiber stimulation. Pain. 2008;138(3):556–64.
35. Rowbotham MC, Fields HL. The relationship of pain, allodynia and thermal
sensation in post-herpetic neuralgia. Brain. 1996;119(Pt 2):347–54.
36. Gierthmühlen J, Maier C, Baron R, Tölle T, Treede RD, Birbaumer N, Huge V,
Koroschetz J, Krumova EK, Lauchart M, Maihöfner C, Richter H. Westermann
A; the German Research Network on Neuropathic Pain (DFNS) study group.
Sensory signs in complex regional pain syndrome and peripheral nerve
injury. Pain. 2012;153(4):765–74.
37. Oaklander AL, Rissmiller JG, Gelman LB, Zheng L, Chang Y, Gott R. Evidence
of focal small-fiber axonal degeneration in complex regional pain syndrome-I
(reflex sympathetic dystrophy). Pain. 2006;120(3):235–43.
38. Krause T, Asseyer S, Geisler F, Fiebach JB, Oeltjenbruns J, Kopf A, Villringer K,
Villringer A, Jungehulsing GJ. Chronic sensory stroke with and without
central pain is associated with bilaterally distributed sensory abnormalities
as detected by Quantitative Sensory Testing. Pain. 2016;157(1):194–202.
39. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D.
The capsaicin receptor: a heat-activated ion channel in the pain pathway.
Nature. 1997;389(6653):816–24.
40. Moran MM, McAlexander MA, Bíró T, Szallasi A. Transient receptor potential
channels as therapeutic targets. Nat Rev Drug Discov. 2011;10(8):601–20.
41. Callsen MG, Moller AT, Sorensen K, Jensen TS, Finnerup NB. Cold
hyposensitivity after topical application of capsaicin in humans. Exp Brain
Res. 2008;191(4):447–52.
42. Kobayashi K, Fukuoka T, Obata K, Yamanaka H, Dai Y, Tokunaga A, Noguchi
K. Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary
afferent neurons with adelta/c-fibers and colocalization with trk receptors.
J Comp Neurol. 2005;493(4):596–606.
43. Okazawa M, Inoue W, Hori A, Hosokawa H, Matsumura K, Kobayashi S.
Noxious heat receptors present in cold-sensory cells in rats. Neurosci Lett.
2004;359(1-2):33–6.
44. Linte RM, Ciobanu C, Reid G, Babes A. Desensitization of cold- and menthol-
sensitive rat dorsal root ganglion neurones by inflammatory mediators. Exp
Brain Res. 2007;178(1):89–98.
45. Attal N, Brasseur L, Chauvin M, Bouhassira D. Effects of single and repeated
applications of a eutectic mixture of local anaesthetics (EMLA) cream on
spontaneous and evoked pain in post-herpetic neuralgia. Pain. 1999;
81(1-2):203–9.
46. Krumova EK, Zeller M, Westermann A, Maier C. Lidocaine patch (5%)
produces a selective, but incomplete block of Aδ and C fibers. Pain. 2012;
153(2):273–80.
47. Weinkauf B, Obreja O, Schmelz M, Rukwied R. Differential effects of lidocaine
on nerve growth factor (NGF)-evoked heat- and mechanical hyperalgesia in
humans. Eur J Pain. 2012;16(4):543–9.
48. Leffler A, Fischer MJ, Rehner D, Kienel S, Kistner K, Sauer SK, Gavva NR, Reeh
PW, Nau C. The vanilloid receptor TRPV1 is activated and sensitized by local
anesthetics in rodent sensory neurons. J Clin Invest. 2008;118(2):763–76.
49. Fuchs PN, Pappagallo M, Meyer RA. Topical EMLA pre-treatment fails to
decrease the pain induced by 1% topical capsaicin. Pain. 1999;80(3):637–42.
50. Westermann A, Rönnau AK, Krumova E, Regeniter S, Schwenkreis P, Rolke R,
Treede RD, Richter H, Maier C. Pain-associated mild sensory deficits without
hyperalgesia in chronic non-neuropathic pain. Clin J Pain. 2011;27(9):782–9.
51. Shenker NG, Haigh RC, Mapp PI, Harris N, Blake DR. Contralateral hyperalgesia
and allodynia following intradermal capsaicin injection in man. Rheumatology
(Oxford). 2008;47(9):1417–21.
52. Drummond PD, Blockey P. Topically applied capsaicin inhibits sensitivity to
touch but not to warmth or heat-pain in the region of secondary mechanical
hyperalgesia. Somatosens Mot Res. 2009;26(4):75–81.
53. van Wijk G, Veldhuijzen DS. Perspective on diffuse noxious inhibitory controls
as a model of endogenous pain modulation in clinical pain syndromes. J Pain.
2010;11(5):408–19.
54. Hartline HK, Ratliff F. Inhibitory interaction of receptor units in the eye of
Limulus. J Gen Physiol. 1957;40(3):357–76.
55. Grill JD, Coghill RC. Transient analgesia evoked by noxious stimulus offset.
J Neurophysiol. 2002;87(4):2205–8.
56. Yelle MD, Rogers JM, Coghill RC. Offset analgesia: a temporal contrast
mechanism for nociceptive information. Pain. 2008;134(1-2):174–86.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Enax-Krumova et al. BMC Neurology  (2017) 17:60 Page 11 of 11
